• Skip to primary navigation
  • Skip to content
  • Skip to footer
Genelex Logo

Genelex

Pharmacogenetics Makes Precision Medicine Possible

  • Patients
    • Conditions
    • Affected Drugs
    • What is PGx?
    • Resources
    • FAQs
    • Patient Stories
  • Providers
    • Resources
    • Order Testing Supplies
  • Test Menu
  • Clinical Trials
  • About
    • Lab Accreditations
    • Genelex Team
    • News
    • Contact Us
  • Log In

CYP2C9

Home / Test Menu / CYP2C9

CYP2C9 Genotyping

Genelex Genotyping CYP2C9CYP2C9 acts on 15% of drugs in current clinical use. About 35% of Caucasians have a slow acting form of this enzyme. CYP2C9 is an important drug-metabolizing enzyme that catalyzes the biotransformation of many other clinically useful drugs including angiotensin II blockers, non-steroidal anti-inflammatory drugs, the alkylating anticancer prodrugs, sulfonylureas, and many others. [29]

Of special interest are those drugs with narrow therapeutic index, such as warfarin (Coumadin®), tolbutamide, and phenytoin (Dilantin®), where impairment in CYP2C9 metabolic activity might cause difficulties in dose adjustment as well as toxicity. Indications for testing include lack of therapeutic effect or difficulties with side effects to any of the drugs metabolized by CYP2C9.

CYP2C9 and VKORC1 variation greatly affect the half-life of warfarin (Coumadin®) and the time it takes to reach a stable dose. VKORC1 is the site of action of warfarin.[30] The level of the enzyme is under genetic control according to the DNA sequence present in the control region of the gene. Inherited differences in VKORC1 increase or decrease the amount of warfarin needed to inhibit the formation of the clotting factors. When the amount of warfarin exceeds what is needed, the risk of bleeding is increased. Indications for testing include lack of therapeutic effect or difficulties with side effects of warfarin.

This test identifies the nine most common alleles of CYP2C9 (*2-*6,*8,*11,*13,*15) and a VKORC1 polymorphism (-1639G>A) which influences warfarin maintenance dose. Analytical specificity and sensitivity for detection of these mutations are >99%.

Indication for CYP2C9 and VKORC1 Testing

For individuals with a personal or family history of adverse drug reactions to warfarin (Coumadin®) and/or other medications metabolized by CYP2C9. Confirm presence of genotypes that affect the metabolism of any drugs that are metabolized by CYP2C9. Confirm presence of CYP2C9, CYP4F2 and VKORC1 (c-1639G>A) genotypes that affect the metabolism of warfarin (Coumadin®).

Insurance Coverage

Check with your insurance provider to determine if CYP2C9 genotyping is covered.  CPT Code is 81227 (provided as guidance only).

Specimen Collection

Click here to order testing supplies or call Client Services at 800-837-8362.

  • Buccal Swabs: 4 sterile buccal swabs
  • Blood: 5-10cc whole blood lavender-top EDTA or yellow-top ACD-A tubes
  • Turnaround Time: 10 business days, faster turnaround available for clinical trials

Individual Genes Tested

CYP2C9
CYP2C19
CYP2D6
CYP3A4 / CYP3A5
ADRA2A
CYP1A2
CYP2B6
CYP4F2 / VKORC1
COMT
DPYD
Factor II - Factor V Leiden
GRIK4
HLA-A or HLA-B
HTR2A
HTR2C
IFNL3
MTHFR
NAT2
OPRM1
SLCO1B1
TPMT
UGT1A1

Improve drug efficacy and start feeling better, faster

Genelex offers a simple, affordable DNA test and provides you with a report that you and your doctor can use to determine which drugs and doses are right for you.

Order Your Test

Footer

CONTACT US

(800) 837-8362
info@genelex.com

3101 Western Ave.
Suite 100
Seattle, WA 98121

HELPFUL INFORMATION

What is PGx?
Test Menu
Conditions
Affected Drugs
Resources
FAQs

ABOUT GENELEX

Blog
News
Genelex Team
Lab Accreditations
Testimonials

  • Facebook
  • LinkedIn
  • RSS
  • Twitter
  • YouTube

KEEP IN TOUCH

Stay in the loop with news and updates from Genelex and be among the first to know when new tests become available.

© GENELEX 2019 ・ PRIVACY POLICY ・ REFERENCES ・ CAP LAB 4344001 ・CLIA 50D0980559 ・NYDOH PFI 8201